TrialAnnals of oncology : official journal of the European Society for Medical Oncology2025

Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.

R J Motzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.